rossannathom
2021-09-14
That’s great news, we need to save more people
J&J reports promising Ebola vaccine data
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":886881586,"tweetId":"886881586","gmtCreate":1631580061745,"gmtModify":1631891429360,"author":{"id":3579310238184228,"idStr":"3579310238184228","authorId":3579310238184228,"authorIdStr":"3579310238184228","name":"rossannathom","avatar":"https://static.tigerbbs.com/fee5c4cb302a57e628de9da574d73fff","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>That’s great news, we need to save more people </p></body></html>","htmlText":"<html><head></head><body><p>That’s great news, we need to save more people </p></body></html>","text":"That’s great news, we need to save more people","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/886881586","repostId":2167369535,"repostType":4,"repost":{"id":"2167369535","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631576934,"share":"https://www.laohu8.com/m/news/2167369535?lang=&edition=full","pubTime":"2021-09-14 07:48","market":"us","language":"en","title":"J&J reports promising Ebola vaccine data","url":"https://stock-news.laohu8.com/highlight/detail?id=2167369535","media":"Reuters","summary":"Sept 13 (Reuters) - Johnson & Johnson said on Monday its Ebola vaccine regimen demonstrated antibody","content":"<p>Sept 13 (Reuters) - Johnson & Johnson said on Monday its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.</p>\n<p>The two-dose regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants, the company said, citing data from a late-stage trial.</p>\n<p>The regimen, Zabdeno and Mvabea, generated immune responses that persisted in adults for at least two years.</p>\n<p>J&J added that there were no safety signals of concern.</p>\n<p>\"These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin,\" J&J's Chief Scientific Officer Paul Stoffels said.</p>\n<p>The company added that a booster shot administered two years after the initial vaccination induced a strong immune response within seven days.</p>\n<p>Ebola typically kills about half of those it infects, although vaccines and new treatments have proven highly effective in reducing fatality rates.</p>\n<p>Last month, the World Health Organisation warned that on top of the COVID-19 pandemic, West Africa is facing new outbreaks of the viral haemorrhagic fevers Marburg and Ebola, risking huge strains on ill-equipped health systems.</p>\n<p>J&J's vaccine regimen had received European approval in July 2020 and prequalification from the WHO, which allows medicines to be procured by developing countries, in April 2021.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J reports promising Ebola vaccine data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J reports promising Ebola vaccine data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-14 07:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 13 (Reuters) - Johnson & Johnson said on Monday its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.</p>\n<p>The two-dose regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants, the company said, citing data from a late-stage trial.</p>\n<p>The regimen, Zabdeno and Mvabea, generated immune responses that persisted in adults for at least two years.</p>\n<p>J&J added that there were no safety signals of concern.</p>\n<p>\"These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin,\" J&J's Chief Scientific Officer Paul Stoffels said.</p>\n<p>The company added that a booster shot administered two years after the initial vaccination induced a strong immune response within seven days.</p>\n<p>Ebola typically kills about half of those it infects, although vaccines and new treatments have proven highly effective in reducing fatality rates.</p>\n<p>Last month, the World Health Organisation warned that on top of the COVID-19 pandemic, West Africa is facing new outbreaks of the viral haemorrhagic fevers Marburg and Ebola, risking huge strains on ill-equipped health systems.</p>\n<p>J&J's vaccine regimen had received European approval in July 2020 and prequalification from the WHO, which allows medicines to be procured by developing countries, in April 2021.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167369535","content_text":"Sept 13 (Reuters) - Johnson & Johnson said on Monday its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.\nThe two-dose regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants, the company said, citing data from a late-stage trial.\nThe regimen, Zabdeno and Mvabea, generated immune responses that persisted in adults for at least two years.\nJ&J added that there were no safety signals of concern.\n\"These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin,\" J&J's Chief Scientific Officer Paul Stoffels said.\nThe company added that a booster shot administered two years after the initial vaccination induced a strong immune response within seven days.\nEbola typically kills about half of those it infects, although vaccines and new treatments have proven highly effective in reducing fatality rates.\nLast month, the World Health Organisation warned that on top of the COVID-19 pandemic, West Africa is facing new outbreaks of the viral haemorrhagic fevers Marburg and Ebola, risking huge strains on ill-equipped health systems.\nJ&J's vaccine regimen had received European approval in July 2020 and prequalification from the WHO, which allows medicines to be procured by developing countries, in April 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":160,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":38,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/886881586"}
精彩评论